Last 12 months
Inside the activity.
15 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 12 | 0 |
| Dec 2025 | 3 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
OtherCommon Stock | 1,200,000 | $2.05 | $2,460,000.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 0 F5 · kind: Represents a cross-trade, pursuant to which Casdin FO1 transferred 1,200,000 shares of Common Stock to the Master Fund and Amplify. F6 · ownership.nature: The securities were owned directly by Casdin FO1 and were deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Casdin FO1, (ii) the GP, the general partner of Casdin FO1, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
OtherCommon Stock | 545,000 | $2.05 | $1,117,250.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 545,000 F3 · kind: Represents a cross-trade, pursuant to which Casdin FO1 transferred 545,000 shares of Common Stock to Casdin Amplify Fund, LP ("Amplify"). F4 · ownership.nature: The securities are owned directly by Amplify and are deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to Amplify, (ii) the GP, the general partner of Amplify, and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| June 18, 2024 Filed Jun 22, 2024 00:53 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
OtherCommon Stock | 655,000 | $2.05 | $1,342,750.00 |
DisclosureSEC source: 0000919574-24-003795 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 46,730,821 F1 · kind: Represents a cross-trade, pursuant to which Casdin Partners FO1-MSV, LP ("Casdin FO1") transferred 655,000 shares of Common Stock to Casdin Partners Master Fund, L.P. (the "Master Fund"). F2 · ownership.nature: The securities are owned directly by the Master Fund and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 23, 2024 Filed May 29, 2024 00:45 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin EliDirector · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
PurchaseCommon Stock | 100,000 | $2.60 | $260,000.00 |
DisclosureSEC source: 0000919574-24-003356 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 46,075,821 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 22, 2024 Filed May 22, 2024 23:53 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin EliDirector · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
PurchaseCommon Stock | 150,000 | $2.58 | $387,735.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,975,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5771 to $2.5865. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 21, 2024 Filed May 22, 2024 23:53 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin EliDirector · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
PurchaseCommon Stock | 350,000 | $2.56 | $895,930.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,825,821 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5597 to $2.56. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:34 UTC |
Kim Hanjoon AlexChief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 750,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0000950170-24-063091 · ownership.xml · derivative · entry 2 Kim Hanjoon Alex · CIK 0001919209 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750,000 Underlying: Common Stock · 750,000 shares Expires 2034-05-20 F2 · derivative.exercise_date: The Option becomes exercisable as to 1/16th of the underlying shares on August 20, 2024, with the remaining shares vesting in equal quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:34 UTC |
Kim Hanjoon AlexChief Operating Officer
|
GrantCommon Stock | 333,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063091 · ownership.xml · nonDerivative · entry 1 Kim Hanjoon Alex · CIK 0001919209 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,401 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 1/16th of the RSUs on August 20, 2024, with the remaining RSUs vesting in equally quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:37 UTC |
Egholm MichaelDirector · President & CEO
|
GrantStock Option (Right to Buy) · Derivative | 2,250,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0000950170-24-063097 · ownership.xml · derivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,250,000 Underlying: Common Stock · 2,250,000 shares Expires 2034-05-20 F2 · derivative.exercise_date: The Option becomes exercisable as to 1/16th of the underlying shares on August 20, 2024, with the remaining shares vesting in equal quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:37 UTC |
Egholm MichaelDirector · President & CEO
|
GrantCommon Stock | 1,000,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063097 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,531,592 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 1/16th of the RSUs on August 20, 2024, with the remaining RSUs vesting in equally quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:35 UTC |
Black Jeffrey G.SVP & Chief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $2.58 | $0.00 |
DisclosureSEC source: 0000950170-24-063094 · ownership.xml · derivative · entry 2 Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Stock · 400,000 shares Expires 2034-05-20 F2 · derivative.exercise_date: The Option becomes exercisable as to 1/16th of the underlying shares on August 20, 2024, with the remaining shares vesting in equal quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:35 UTC |
Black Jeffrey G.SVP & Chief Financial Officer
|
GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-063094 · ownership.xml · nonDerivative · entry 1 Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 419,836 F1 · shares: Represents Restricted Stock Units ("RSUs") that vest as to 1/16th of the RSUs on August 20, 2024, with the remaining RSUs vesting in equally quarterly installments over four years thereafter, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. Read SEC document |
| May 20, 2024 Filed May 22, 2024 23:53 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin EliDirector · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
PurchaseCommon Stock | 100,000 | $2.58 | $258,130.00 |
DisclosureSEC source: 0000919574-24-003308 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 45,475,821 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5791 to $2.5858. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 17, 2024 Filed May 18, 2024 00:11 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin EliDirector · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
PurchaseCommon Stock | 352,072 | $2.56 | $902,043.67 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 45,375,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5381 to $2.5798. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 16, 2024 Filed May 18, 2024 00:11 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin EliDirector · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
PurchaseCommon Stock | 500,000 | $2.54 | $1,270,950.00 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 45,023,749 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5381 to $2.5429. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 15, 2024 Filed May 17, 2024 01:07 UTC |
Black Jeffrey G.SVP & Chief Financial Officer
|
Exercise / conversionCommon Stock · Derivative | 52,631 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061315 · ownership.xml · derivative · entry 3 Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,895 Underlying: Common Stock · 52,631 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: On May 15, 2023, the Reporting Person was granted 210,526 RSUs. 1/4th of the RSUs vested on May 15, 2024 and the remaining RSUs will vest in twelve equal quarterly installments thereafter. F3 · derivative.expiration_date: On May 15, 2023, the Reporting Person was granted 210,526 RSUs. 1/4th of the RSUs vested on May 15, 2024 and the remaining RSUs will vest in twelve equal quarterly installments thereafter. Read SEC document |
| May 15, 2024 Filed May 17, 2024 01:07 UTC |
Black Jeffrey G.SVP & Chief Financial Officer
|
Tax withholdingCommon Stock | 18,779 | $2.54 | $47,698.66 |
DisclosureSEC source: 0000950170-24-061315 · ownership.xml · nonDerivative · entry 2 Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,836 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of restricted stock units ("RSUs") granted to the reporting person on May 15, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on May 17, 2023. Read SEC document |
| May 15, 2024 Filed May 17, 2024 01:07 UTC |
Black Jeffrey G.SVP & Chief Financial Officer
|
Exercise / conversionCommon Stock | 52,631 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-061315 · ownership.xml · nonDerivative · entry 1 Black Jeffrey G. · CIK 0001449439 · SVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:11 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin EliDirector · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
PurchaseCommon Stock | 500,000 | $2.57 | $1,282,550.00 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 44,523,749 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5473 to $2.58. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| April 08, 2024 Filed Apr 9, 2024 23:11 UTC |
Egholm MichaelDirector · President & CEO
|
Tax withholdingCommon Stock | 102,564 | $2.71 | $277,948.44 |
DisclosureSEC source: 0000950170-24-043103 · ownership.xml · nonDerivative · entry 1 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 531,592 F1 · shares: The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain performance-based restricted stock units ("RSUs") granted to the reporting person on April 11, 2023, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on April 5, 2024 upon the determination by the Board of Directors of the Issuer that certain of the performance-based conditions were met. Read SEC document |
| April 05, 2024 Filed Apr 5, 2024 22:58 UTC |
Kim Hanjoon AlexChief Operating Officer
|
GrantCommon Stock | 70,702 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042372 · ownership.xml · nonDerivative · entry 2 Kim Hanjoon Alex · CIK 0001919209 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,068 F1 · shares: On April 11, 2023, the Reporting Person was granted a target amount of 77,185 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 70,702 RSUs as of March 31, 2024. Read SEC document |
| April 05, 2024 Filed Apr 5, 2024 22:59 UTC |
Egholm MichaelDirector · President & CEO
|
GrantCommon Stock | 212,126 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042373 · ownership.xml · nonDerivative · entry 3 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 634,156 F2 · shares: On April 11, 2023, the Reporting Person was granted a target amount of 231,579 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 212,126 RSUs as of March 31, 2024. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 22:58 UTC |
Kim Hanjoon AlexChief Operating Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 70,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042372 · ownership.xml · derivative · entry 3 Kim Hanjoon Alex · CIK 0001919209 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,366 Underlying: Common Stock · 70,183 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: On April 4, 2022, the Reporting Person was granted 280,732 RSUs, vesting in four equal annual installments beginning on April 4, 2023. F3 · derivative.expiration_date: On April 4, 2022, the Reporting Person was granted 280,732 RSUs, vesting in four equal annual installments beginning on April 4, 2023. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 22:58 UTC |
Kim Hanjoon AlexChief Operating Officer
|
Exercise / conversionCommon Stock | 70,183 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042372 · ownership.xml · nonDerivative · entry 1 Kim Hanjoon Alex · CIK 0001919209 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 22:59 UTC |
Egholm MichaelDirector · President & CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 196,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042373 · ownership.xml · derivative · entry 4 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 393,025 Underlying: Common Stock · 196,512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. F4 · derivative.expiration_date: On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 22:59 UTC |
Egholm MichaelDirector · President & CEO
|
Exercise / conversionCommon Stock | 196,512 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-042373 · ownership.xml · nonDerivative · entry 2 Egholm Michael · CIK 0001559779 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
Disposition to issuerSeries B-1 Convertible Preferred Stock · Derivative | 38,334 | $2.75 Strike: $2.75 | $105,418.50 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · derivative · entry 8 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,939,637 shares Expires not disclosed F7 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F7 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F2 · ownership.nature: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
Disposition to issuerSeries B-1 Convertible Preferred Stock · Derivative | 89,446 | $2.75 Strike: $2.75 | $245,976.50 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · derivative · entry 7 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 32,525,821 shares Expires not disclosed F7 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F7 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
GrantCommon Stock | 13,939,637 | $2.75 | $38,334,001.75 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 13,939,637 F2 · ownership.nature: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
GrantCommon Stock | 32,525,821 | $2.75 | $89,446,007.75 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 44,023,749 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:20 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
PurchaseCommon Stock | 1,403 | $2.62 | $3,668.85 |
DisclosureSEC source: 0000919574-24-001888 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,497,928 F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:20 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
Casdin EliDirector · 10% owner
|
PurchaseCommon Stock | 250,000 | $2.57 | $642,500.00 |
DisclosureSEC source: 0000919574-24-001888 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,496,525 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.5525 to $2.616. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 22:01 UTC |
Casdin EliDirector · 10% owner
|
GrantCommon Stock | 22,800 | $2.50 | $57,000.00 |
DisclosureSEC source: 0000950170-24-018893 · ownership.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,556 F1 · shares: Represents Restricted Stock Units that vest in four equal quarterly installments beginning on March 15, 2024. The Reporting Person has deferred settlement of the Restricted Stock Units until the earlier to occur of the Reporting Person's termination of service and a change of control. F2 · price: The Restricted Stock Units were issued to the Reporting Person, who elected to take Restricted Stock Units in lieu of $57,000 in cash compensation for services as a board member. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 01:51 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
GrantCommon Stock | 2,744,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-24-000224 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,744,219 F2 · price: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. F2 · ownership.nature: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 01:51 UTC |
Casdin Partners Master Fund, L.P.Director · 10% owner
Casdin Capital, LLCDirector · 10% owner
Casdin Partners GP, LLCDirector · 10% owner
Casdin Partners FO1-MSV, LPDirector
|
GrantCommon Stock | 11,246,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-24-000224 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,246,525 F1 · price: Received in exchange for 10,132,005 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. F1 · ownership.direct: Received in exchange for 10,132,005 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantWarrant to purchase common stock (Right to buy) · Derivative | 4,824,802 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 11 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · CMLS Holdings LLC Disclosed balance after: 4,824,802 Underlying: Common Stock · 4,824,802 shares Expires 2026-09-01 F12 · shares: 25% of the shares underlying the option vested on February 19, 2022, with the remaining shares vesting in equally monthly installments started on the 1st day of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. F13 · price: Pursuant to the Merger Agreement, each warrant to purchase SomaLogic common stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of common stock of the Company equal to multiplying the number of shares of common stock of SomaLogic subject to such warrant by the Exchange Ratio. The securities are held of record by CMLS Holdings II. See footnote 4 for more information. F12 · ownership.nature: 25% of the shares underlying the option vested on February 19, 2022, with the remaining shares vesting in equally monthly installments started on the 1st day of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantStock Option (Right to buy) · Derivative | 46,514 | Not disclosed Strike: $4.30 | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 10 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,514 Underlying: Common Stock · 46,514 shares Expires 2031-02-18 F9 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F12 · derivative.exercise_date: 25% of the shares underlying the option vested on February 19, 2022, with the remaining shares vesting in equally monthly installments started on the 1st day of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantStock Option (Right to buy) · Derivative | 22,866 | Not disclosed Strike: $2.08 | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 9 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,866 Underlying: Common Stock · 22,866 shares Expires 2033-03-16 F9 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F11 · derivative.exercise_date: 100% of the shares underlying the option vest on March 17, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantStock Option (Right to buy) · Derivative | 22,866 | Not disclosed Strike: $8.19 | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 8 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,866 Underlying: Common Stock · 22,866 shares Expires 2032-02-29 F9 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F10 · derivative.exercise_date: This option is fully vested and currently exercisable. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantStock Option (Right to buy) · Derivative | 51,842 | Not disclosed Strike: $10.68 | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · derivative · entry 7 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,842 Underlying: Common Stock · 51,842 shares Expires 2031-10-26 F9 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Issuer's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F8 · derivative.exercise_date: 25% of the shares underlying the option vested on October 27, 2022, with the remaining shares vesting in equal monthly installments thereafter starting on the 1st of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantCommon Stock | 2,744,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 5 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Casdin Private Growth Equity Fund, L.P. Disclosed balance after: 2,744,219 F6 · shares: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC. F6 · price: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC. F6 · ownership.nature: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. The shares held by Casdin Private Growth Equity Fund, L.P. may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Private Growth Equity GP, LLC, the general partner of Casdin Private Growth Equity Fund, L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Private Growth Equity GP, LLC. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantCommon Stock | 11,246,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 4 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By Casdin Partners Master Fund, L.P. Disclosed balance after: 11,246,525 F5 · shares: Received in exchange for 10,132,055 shares of common stock of SomaLogic pursuant to the Merger. The shares reflected as beneficially owned by Casdin Partners Master Fund, L.P. in the table above are owned directly by Casdin Partners Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. F5 · price: Received in exchange for 10,132,055 shares of common stock of SomaLogic pursuant to the Merger. The shares reflected as beneficially owned by Casdin Partners Master Fund, L.P. in the table above are owned directly by Casdin Partners Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. F5 · ownership.nature: Received in exchange for 10,132,055 shares of common stock of SomaLogic pursuant to the Merger. The shares reflected as beneficially owned by Casdin Partners Master Fund, L.P. in the table above are owned directly by Casdin Partners Master Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Partners Master Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Partners Master Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantCommon Stock | 7,548,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 3 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Indirect · By CMLS Holdings II LLC Disclosed balance after: 7,548,000 F4 · shares: Received in exchange for 6,800,000 shares of common stock of SomaLogic pursuant to the Merger. The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings III, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which inlcude such shares and the warrants referenced in Table II. F4 · price: Received in exchange for 6,800,000 shares of common stock of SomaLogic pursuant to the Merger. The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings III, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which inlcude such shares and the warrants referenced in Table II. F4 · ownership.nature: Received in exchange for 6,800,000 shares of common stock of SomaLogic pursuant to the Merger. The shares are held of record by CMLS Holdings II LLC ("CMLS Holdings II"). The Board of Managers of CMLS Holdings II includes Mr. Casdin, who, as a member of the Board of Managers of CMLS Holdings III, shares voting and investment discretion with respect to the common stock held by CMLS Holdings II. Mr. Casdin may be deemed to have or share beneficial ownership of the securities held by CMLS Holdings II, which inlcude such shares and the warrants referenced in Table II. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantCommon Stock | 3,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 2 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,756 F2 · shares: Represents Restricted Stock Units ("RSUs") that vest in four equal annual installments beginning March 17, 2024, subject to the Reporting Person's continued service through the applicable vesting date. Each RSU represents the right to receive one share of common stock upon vesting. F3 · price: Pursuant to the Merger Agreement, each RSU convertible into shares of SomaLogic common stock (a "SomaLogic RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of common stock of the Company equal to the to the product of (i) the number of shares subject to such SomaLogic RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, with the resulting number of shares of Company common stock rounded to the next nearest whole share. Except as noted above, each assumed SomaLogic RSU will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic RSU immediately prior to the Effective Time. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:06 UTC |
Casdin EliDirector · 10% owner
|
GrantCommon Stock | 3,807 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-002655 · tm242400-7_4seq1.xml · nonDerivative · entry 1 Casdin Eli · CIK 0001534264 · Director · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,949 F1 · shares: Received in exchange for 3,430 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). F1 · price: Received in exchange for 3,430 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:05 UTC |
Cox TroyDirector
|
GrantWarrant to purchase Common Stock (Right to buy) · Derivative | 184,999 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 8 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,999 Underlying: Common Stock · 184,999 shares Expires 2026-09-01 F10 · price: Pursuant to the Merger Agreement, each warrant to purchase SomaLogic common stock was treated in accordance with its terms on and after the Effective Time and each warrant will convert into the right to receive, upon exercise of such warrant, the number of shares of common stock of the Company equal to multiplying the number of shares of common stock of SomaLogic subject to such warrant by the Exchange Ratio. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:05 UTC |
Cox TroyDirector
|
GrantStock Option (Right to buy) · Derivative | 190,365 | Not disclosed Strike: $2.08 | Not disclosed |
DisclosureSEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 7 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,365 Underlying: Common Stock · 190,365 shares Expires 2033-03-16 F6 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F9 · derivative.exercise_date: 25% of the shares underlying the option vest on March 17, 2024, with the remaining shares vesting in equal monthly installments thereafter starting on the 1st of following full month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:05 UTC |
Cox TroyDirector
|
GrantStock Option (Right to buy) · Derivative | 982,811 | Not disclosed Strike: $2.60 | Not disclosed |
DisclosureSEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 6 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 982,811 Underlying: Common Stock · 928,811 shares Expires 2032-10-16 F6 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F8 · derivative.exercise_date: One third of the shares underlying the option vested on October 17, 2023, with the remaining shares vesting in equal monthly installments thereafter starting on the 1st of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:05 UTC |
Cox TroyDirector
|
GrantStock Option (Right to buy) · Derivative | 22,866 | Not disclosed Strike: $8.18 | Not disclosed |
DisclosureSEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 5 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,866 Underlying: Common Stock · 22,866 shares Expires 2032-02-29 F6 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F7 · derivative.exercise_date: This option is fully vested and currently exercisable. Read SEC document |
| January 05, 2024 Filed Jan 9, 2024 23:05 UTC |
Cox TroyDirector
|
GrantStock Option (Right to buy) · Derivative | 51,842 | Not disclosed Strike: $10.68 | Not disclosed |
DisclosureSEC source: 0001104659-24-002654 · tm242400-6_4seq1.xml · derivative · entry 4 Cox Troy · CIK 0001696923 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,842 Underlying: Common Stock · 51,842 shares Expires 2031-10-26 F6 · price: Pursuant to the Merger Agreement, each option to purchase SomaLogic common stock (a "SomaLogic Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time, was converted into an option to acquire the number of shares of common stock of the Company equal to the product of (i) the number of shares subject to such SomaLogic Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio, rounded down to the nearest whole number of shares of the Company's common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the SomaLogic Option by the Exchange Ratio, rounded up to the nearest whole cent. Except as noted above, each assumed SomaLogic Option will continue to be governed by the same terms and conditions, including vesting terms and provision, as were applicable to such SomaLogic Option immediately prior to the Effective Time. F5 · derivative.exercise_date: 25% of the shares underlying the option vested on October 27, 2022, with the remaining shares vesting in equal monthly installments thereafter starting on the 1st of the following month until fully vested, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.